The group’s latest deal is with a company called United Italian Trading Corporation (UITC), which has landed the exclusive rights to distribute the cholesterol-lowering product line, CholBiomeX3, in Singapore.
UITC, whose customers include hospitals, clinics, doctors’ surgeries, and pharmacies, has agreed to order 5,000 boxes for delivery by the end of the year and increasing annual minimum order quantities to retain its exclusivity.
OptiBiotix said the agreement was another example of the “increasing number of pharmaceutical companies commercialising CholBiome products into the high-value GP, hospital and pharmacy markets”.
In a statement, Mikkel Hvid-Hansen, commercial director of OptiBiotix’s ProBiotix Health division commented: “As the gap between drugs and probiotics developed using more rigorous scientific and clinical approaches narrows, we can see these so-called next-generation probiotics, increasingly being seen as mainstream treatment options.”
This content was originally published here.